yttrium-90 edotreotide

Yttrium-90 edotreotide is a **radiopharmaceutical** composed of the somatostatin analogue edotreotide chemically linked to the beta-emitting radioisotope yttrium-90 via a DOTA chelator[1][4][7]. It binds to **somatostatin receptors (SSTRs)**, especially subtype 2, which are highly expressed on the surface of **neuroendocrine tumors (NETs)**, delivering targeted beta radiation that induces cytotoxicity in tumor cells while sparing nearby healthy tissue[1][4][7]. The drug demonstrated significant anti-tumor activity and symptomatic benefit in phase I and II trials for metastatic, somatostatin-receptor-positive NETs, including carcinoid tumors refractory to octreotide[1][7]. Although effective (response or stable disease rates of 66–92%), research and clinical usage has decreased in favor of lutetium-177 based analogs due to a superior efficacy and safety profile[1][7]. Key toxicities included kidney toxicity and bone marrow suppression, so renal-protective protocols such as amino acid co-infusion were used in clinical practice[1][7]. The patent expired in 2015 in Europe.

Brand names

Onalta

Other names

Edotreotide yttrium Y-90Edotreotide 90Y chelateEdotreotide90Y chelateEdotreotide-90Y chelateYttrium 90Y edotreotideYttrium90Y edotreotideYttrium-90Y edotreotideYttrium-90 DOTATOCYttrium90 DOTATOCYttrium 90 DOTATOC